mirabegron

12/01/2018 - "Mirabegron has an excellent safety profile and appears to be an effective treatment for overactive bladder symptoms in patients with PD. "
01/01/2014 - "In Phase III clinical trials in patients with overactive bladder (OAB), mirabegron at daily doses of 25, 50, and 100 mg demonstrated significant efficacy in treating the symptoms of OAB, including micturition frequency, urgency incontinence, and urgency. "
09/01/2018 - "The present study assessed the therapeutic efficacy and safety of mirabegron 25 mg in older patients aged ≥80 years with overactive bladder and multiple comorbidities. "
04/01/2019 - "Mirabegron is widely considered as an effective and safe drug for patients with overactive bladder (OAB). "
01/01/2019 - "Re: Safety and Therapeutic Efficacy of Mirabegron 25 mg in Older Patients with Overactive Bladder and Multiple Comorbidities."

01/01/2020 - "This was a prospective, open-label 12-week trial evaluating the efficacy of mirabegron in 34 men and women with disordered sleep and lower urinary tract symptoms (LUTS). "
01/01/2022 - "Effects of β3-adrenergic agonists on prostate smooth muscle contraction are poorly characterized, although mirabegron is used for treatment of lower urinary tract symptoms. "
01/01/2022 - "Mirabegron improves urinary characteristics and the associated sexual dysfunction in patients with lower urinary tract symptoms/benign prostatic obstruction."
12/01/2013 - "Mirabegron for male lower urinary tract symptoms."
01/01/2022 - "To assess the efficacy of mirabegron in the treatment of erectile dysfunction concomitant with lower urinary tract symptoms in benign prostatic obstruction patients. "

01/01/2021 - "We found that mirabegron treatment resulted in a significant improvement in bladder compliance [mean difference (MD) = 19.53, 95% confidence interval (CI): 14.19 to 24.87, P < 0.00001], urinary incontinence episodes (MD = -0.78, 95% CI: -0.89 to -0.67, P < 0.00001) and Incontinence Quality of Life (I-QOL) (MD = 8.02, 95% CI: 3.20 to 12.84, P = 0.001). "
01/01/2015 - "After mirabegron, urinary incontinence was improved in all patients. "
01/01/2021 - "This 12-week study included patients who were starting mirabegron treatment for the OAB symptoms of urinary urgency, daytime frequency, and urgency urinary incontinence. "
01/01/2016 - "A meta-analysis of four placebo-controlled trials including about 3500 patients suggested that mirabegron was poorly effective: on average, treatment prevented one episode of urinary incontinence every 2 days."
04/27/2023 - "Mirabegron treatment was associated with a lower number of urinations and occurrences of urinary incontinence per day. "

01/01/2020 - "Mirabegron use improves nocturia and produces rapid, durable, and clinically significant improvement in sleep disturbance and LUTS in males and females with urinary symptoms associated with disordered sleep."
01/01/2018 - "Both mirabegron 50 mg and mirabegron 100 mg were associated with a significant reduction of nocturia episodes when compared with a placebo. "
01/01/2020 - "Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive bladder."
01/01/2020 - "The objective of this study was to evaluate the efficacy of mirabegron 25 mg daily in patients with nocturia-predominant hypersensitive bladder (HSB). "
01/01/2022 - "Pooled analysis of data from prospective randomized studies on >60,000 OAB patients showed that when compared to placebo, mirabegron was superior with respect to reducing the frequency, number, and severity of urgency episodes, number of incontinence episodes and increasing dry rate, but not in reduction of nocturia episodes. "

01/01/2022 - "In the elderly patients with low detrusor contractility, with central nervous system lesion, and men with benign prostatic hyperplasia, starting from 25 mg mirabegron is recommended. "
01/01/2020 - "Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study."
01/01/2021 - "Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post-marketing study."
01/07/2021 - "To review the efficacy and safety of mirabegron in men with overactive bladder (OAB) and benign prostatic hyperplasia (BPH). "
01/07/2021 - "Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia."